O	0	3	The
O	4	11	outcome
O	12	18	effect
O	19	21	of
B-intervention	22	28	double
I-intervention	28	29	-
I-intervention	29	37	hormonal
I-intervention	38	45	therapy
O	46	48	in
O	49	62	premenopausal
O	63	69	breast
O	70	76	cancer
O	77	85	patients
O	86	90	with
O	91	95	high
O	96	101	nodal
O	101	102	-
O	102	108	status
O	108	109	:
O	110	116	Result
O	117	119	of
O	120	121	a
O	122	133	prospective
O	134	144	randomized
O	145	150	trial
O	150	151	.

O	152	155	The
O	156	167	combination
O	168	170	of
O	171	178	taxanes
O	179	182	and
O	183	197	anthracyclines
O	198	201	has
O	202	208	proven
O	209	217	efficacy
O	218	220	in
O	221	225	node
O	225	226	-
O	226	234	positive
O	235	236	(
O	236	237	N
O	237	238	+
O	238	239	)
O	240	253	premenopausal
O	254	261	primary
O	262	268	breast
O	269	275	cancer
O	276	284	patients
O	284	285	.

O	286	293	Ovarian
O	294	302	ablation
O	303	305	is
O	306	310	also
O	311	321	associated
O	322	326	with
O	327	333	better
O	334	342	survival
O	343	351	outcomes
O	352	354	in
O	355	368	premenopausal
O	369	376	hormone
O	376	377	-
O	377	385	receptor
O	386	394	positive
O	395	396	(
O	396	398	HR
O	398	399	+
O	399	400	)
O	401	409	patients
O	409	410	.

O	411	420	Therefore
O	420	421	,
O	422	426	this
O	427	432	trial
O	433	437	aims
O	438	440	to
O	441	450	determine
O	451	454	the
O	455	466	superiority
O	467	469	of
O	470	478	combined
O	479	487	hormonal
O	488	497	treatment
O	498	500	of
O	501	508	ovarian
O	509	517	ablation
O	518	522	with
O	523	532	tamoxifen
O	533	534	(
O	534	537	TMX
O	537	538	)
O	539	545	versus
O	546	549	TMX
O	550	555	alone
O	555	556	,
O	557	559	in
O	560	573	premenopausal
O	574	575	N
O	575	576	+
O	576	577	,
O	578	580	HR
O	581	582	+
O	583	591	patients
O	592	601	receiving
O	602	610	adjuvant
O	611	623	chemotherapy
O	624	625	(
O	625	627	AC
O	627	628	)
O	629	633	with
O	634	640	taxane
O	641	644	and
O	645	658	anthracycline
O	658	659	.

B-eligibility	660	673	Premenopausal
I-eligibility	674	679	women
I-eligibility	680	683	who
I-eligibility	684	687	had
I-eligibility	688	698	surgically
I-eligibility	699	706	removed
I-eligibility	707	713	breast
I-eligibility	714	720	cancer
I-eligibility	721	725	with
I-eligibility	726	740	histologically
I-eligibility	741	750	confirmed
I-eligibility	751	752	N
I-eligibility	753	754	+
I-eligibility	755	758	and
I-eligibility	759	761	HR
I-eligibility	761	762	+
O	763	767	were
O	768	776	included
O	777	779	in
O	780	783	the
O	784	789	trial
O	789	790	.

O	791	794	The
O	795	797	AC
O	798	807	consisted
O	808	810	of
O	811	814	six
O	815	821	cycles
O	822	824	of
O	825	833	taxotere
O	833	834	,
O	835	845	adriamycin
O	845	846	,
O	847	854	cytoxan
O	855	857	or
O	858	866	taxotere
O	866	867	,
O	868	878	epirubicin
O	879	882	and
O	883	890	cytoxan
O	891	895	with
O	896	899	the
O	900	910	completion
O	911	913	of
O	914	923	radiation
O	924	931	therapy
O	931	932	.

O	933	941	Patients
O	942	946	were
O	947	955	randomly
O	956	964	assigned
O	965	967	to
O	968	975	receive
B-control	976	979	TMX
O	980	982	20
O	983	985	mg
O	985	986	/
O	986	989	day
O	990	993	for
O	994	995	5
O	996	1001	years
O	1002	1004	or
O	1005	1007	up
O	1008	1010	to
O	1011	1020	menopause
O	1021	1023	or
O	1024	1027	TMX
O	1028	1030	20
O	1031	1033	mg
O	1033	1034	/
O	1034	1037	day
O	1038	1041	for
O	1042	1043	5
O	1044	1049	years
O	1050	1054	plus
O	1055	1064	goserelin
O	1065	1066	(
O	1066	1069	GOS
O	1069	1070	)
O	1071	1072	3
O	1072	1073	.
O	1073	1074	6
O	1075	1077	mg
O	1078	1087	injection
O	1088	1091	per
O	1092	1097	month
O	1098	1101	for
O	1102	1103	2
O	1104	1109	years
O	1109	1110	.

O	1111	1114	The
O	1115	1122	primary
O	1123	1126	end
O	1127	1132	point
O	1133	1136	was
B-outcome-Measure	1137	1144	disease
I-outcome-Measure	1144	1145	-
I-outcome-Measure	1145	1149	free
I-outcome-Measure	1150	1158	survival
I-outcome-Measure	1159	1160	(
I-outcome-Measure	1160	1163	DFS
I-outcome-Measure	1163	1164	)
O	1164	1165	.

O	1166	1173	Between
O	1174	1178	2003
O	1179	1182	and
O	1183	1187	2011
O	1187	1188	,
B-total-participants	1189	1192	101
O	1193	1204	consecutive
O	1205	1213	patients
O	1214	1218	were
O	1219	1228	allocated
O	1229	1231	to
O	1232	1235	TMX
O	1236	1237	(
B-control-participants	1237	1239	51
O	1240	1248	patients
O	1248	1249	)
O	1250	1253	and
O	1254	1257	TMX
O	1257	1258	/
O	1258	1261	GOS
O	1262	1263	(
B-intervention-participants	1263	1265	50
O	1266	1274	patients
O	1274	1275	)
O	1276	1282	groups
O	1282	1283	.

O	1284	1287	The
O	1288	1292	mean
O	1293	1299	follow
O	1299	1300	-
O	1300	1302	up
O	1303	1309	period
O	1310	1313	was
O	1314	1316	52
O	1316	1317	.
O	1317	1318	4
O	1319	1320	±
O	1321	1322	2
O	1322	1323	.
O	1323	1324	8
O	1325	1331	months
O	1331	1332	.

B-outcome	1333	1336	DFS
O	1337	1340	was
B-cv-cont-mean	1341	1343	43
I-cv-cont-mean	1343	1344	.
I-cv-cont-mean	1344	1345	0
O	1346	1347	±
B-cv-cont-sd	1348	1349	3
I-cv-cont-sd	1349	1350	.
I-cv-cont-sd	1350	1351	6
I-cv-cont-sd	1352	1358	months
O	1359	1365	versus
B-iv-cont-mean	1366	1368	49
I-iv-cont-mean	1368	1369	.
I-iv-cont-mean	1369	1370	9
O	1371	1372	±
B-iv-cont-sd	1373	1374	4
I-iv-cont-sd	1374	1375	.
I-iv-cont-sd	1375	1377	22
I-iv-cont-sd	1378	1384	months
O	1385	1386	(
O	1386	1387	P
O	1388	1389	=
O	1390	1391	0
O	1391	1392	.
O	1392	1394	13
O	1394	1395	)
O	1396	1399	and
B-outcome	1400	1407	overall
I-outcome	1408	1416	survival
O	1417	1420	was
B-cv-cont-mean	1421	1423	51
I-cv-cont-mean	1423	1424	.
I-cv-cont-mean	1424	1425	1
O	1426	1427	±
B-cv-cont-sd	1428	1429	3
I-cv-cont-sd	1429	1430	.
I-cv-cont-sd	1430	1431	8
I-cv-cont-sd	1432	1438	months
O	1439	1445	versus
B-iv-cont-mean	1446	1448	53
I-iv-cont-mean	1448	1449	.
I-iv-cont-mean	1449	1450	1
O	1451	1452	±
B-iv-cont-sd	1453	1454	4
I-iv-cont-sd	1454	1455	.
I-iv-cont-sd	1455	1456	2
I-iv-cont-sd	1457	1463	months
O	1464	1465	(
O	1465	1466	P
O	1467	1468	=
O	1469	1470	0
O	1470	1471	.
O	1471	1473	50
O	1473	1474	)
O	1475	1477	in
O	1478	1481	the
O	1482	1485	TMX
O	1486	1489	and
O	1490	1493	TMX
O	1493	1494	/
O	1494	1497	GOS
O	1498	1504	groups
O	1504	1505	,
O	1506	1518	respectively
O	1518	1519	.

O	1520	1523	The
O	1524	1531	results
O	1532	1538	showed
O	1539	1540	9
O	1540	1541	%
O	1542	1550	absolute
B-outcome	1551	1555	risk
I-outcome	1556	1565	reduction
O	1566	1570	with
O	1571	1578	respect
O	1579	1581	to
O	1582	1585	DFS
O	1586	1588	in
O	1589	1594	favor
O	1595	1597	of
O	1598	1601	the
O	1602	1605	TMX
O	1605	1606	/
O	1606	1609	GOS
O	1610	1615	group
O	1615	1616	.

O	1617	1621	This
O	1622	1627	study
O	1628	1633	group
O	1634	1637	was
O	1638	1647	comprised
O	1648	1650	of
O	1651	1656	stage
O	1657	1659	II
O	1660	1663	and
O	1664	1667	III
O	1668	1675	disease
O	1676	1684	patients
O	1685	1689	with
O	1690	1694	high
O	1695	1700	nodal
O	1701	1707	status
O	1707	1708	.

O	1709	1712	The
O	1713	1716	TMX
O	1716	1717	/
O	1717	1720	GOS
O	1721	1732	combination
O	1733	1740	reduced
O	1741	1749	absolute
O	1750	1754	risk
O	1755	1757	of
O	1758	1768	developing
O	1769	1774	first
O	1775	1787	locoregional
O	1788	1790	or
O	1791	1798	distant
O	1799	1806	relapse
O	1807	1809	by
O	1810	1816	almost
O	1817	1818	9
O	1818	1819	%
O	1819	1820	.

O	1821	1827	Longer
O	1828	1834	follow
O	1834	1835	-
O	1835	1837	up
O	1838	1840	is
O	1841	1849	required
O	1850	1852	to
O	1853	1860	justify
O	1861	1865	this
O	1866	1874	protocol
O	1875	1878	for
O	1879	1886	routine
O	1887	1890	use
O	1890	1891	.
